Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis
Type 2 diabetes mellitus (T2DM) associated non-alcoholic fatty liver disease (NAFLD) is the
fourth-leading cause of death. Hyperglycemia induces various complications, including …
fourth-leading cause of death. Hyperglycemia induces various complications, including …
Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis
S Kumar, Q Duan, R Wu, EN Harris, Q Su - Advanced drug delivery reviews, 2021 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease that encompasses a
spectrum of pathological conditions, ranging from simple steatosis (NAFL), nonalcoholic …
spectrum of pathological conditions, ranging from simple steatosis (NAFL), nonalcoholic …
[HTML][HTML] Liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies
Metabolic-associated fatty liver disease (MAFLD) is a new disease definition, and this
nomenclature MAFLD was proposed to renovate its former name, non-alcoholic fatty liver …
nomenclature MAFLD was proposed to renovate its former name, non-alcoholic fatty liver …
Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis
Non-alcoholic fatty liver disease (NAFLD) is a cluster of several liver diseases like hepatic
steatosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver (NAFL), liver …
steatosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver (NAFL), liver …
[HTML][HTML] Current options and future directions for NAFLD and NASH treatment
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide, with a broad spectrum ranging from simple steatosis to advanced stage of …
worldwide, with a broad spectrum ranging from simple steatosis to advanced stage of …
Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder globally
impacting an estimated 25% of the population associated with severe consequences such …
impacting an estimated 25% of the population associated with severe consequences such …
TGF-β1 signaling can worsen NAFLD with liver fibrosis backdrop
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) is characterized by the accumulation of
fats in the liver. Relatively benign NAFLD often progresses to fibrosis, cirrhosis, and liver …
fats in the liver. Relatively benign NAFLD often progresses to fibrosis, cirrhosis, and liver …
Nonalcoholic fatty liver disease: current and potential therapies
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury
worldwide. It covers a wide spectrum of hepatic disorders ranging from simple steatosis …
worldwide. It covers a wide spectrum of hepatic disorders ranging from simple steatosis …
[HTML][HTML] Treating inflammation to combat non-alcoholic fatty liver disease
L Wiering, F Tacke - Journal of Endocrinology, 2023 - joe.bioscientifica.com
Non-alcoholic fatty liver disease (NAFLD) with its more progressive form non-alcoholic
steatohepatitis (NASH) has become the most common chronic liver disease, thereby …
steatohepatitis (NASH) has become the most common chronic liver disease, thereby …
[HTML][HTML] Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
L Rong, J Zou, W Ran, X Qi, Y Chen, H Cui… - Frontiers in …, 2023 - frontiersin.org
Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid
deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia …
deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia …